Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Remedy extensive report: Checkpoint reached, heading towards the next platform leap

REMEDYExtensive research19.11.2026, 10.18
Atte RiikolaAnalyst
Discuss
Read the full report

Summary

  • The analyst reiterates the EUR 21.0 target price and upgrades Remedy to Buy from Accumulate following the share price decline.
  • Control Resonant sold over 1 million copies in about three weeks, Remedy’s fastest-selling game. The analyst expects it to be highly profitable and says the launch reduces short-term risk and enables future self-publishing.
  • Although hit-game upside did not materialize, the analyst considers the valuation attractive at 2027e–2028e EV/EBITDA of 8x–6x. The DCF base-case value is EUR 22.8.
  • The analyst forecasts 2027 revenue of 113 MEUR and EBITDA of 23.2 MEUR, rising to 32.3 MEUR in 2028. Game sales and release timing will keep results volatile.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 11/19/2026 at 8:00 am EET

We reiterate our EUR 21.0 target price for Remedy, but following the share price drop, we update our recommendation to Buy (was Accumulate). Control Resonant has been successfully launched, and although the hit game option did not materialize, we estimate the game will be a commercially highly profitable project for Remedy. The successful launch of Resonant also reduces Remedy's short-term risks and, in our view, enables the self-publishing of future projects. Relative to this potential, we find the share valuation highly attractive.

An independent AAA game developer and publisher

In 2017, Remedy began its transition to a multi-project model and a journey up the value chain from a subcontractor to an independent game developer and publisher. Since then, much progress has been made, and the company now has the resources and capabilities to develop two projects simultaneously in full production. The company has also built the capabilities to self-publish its own games. As a result, the revenue and profit potential of games for Remedy is significantly higher than in previous game projects. Control Resonant, launched in September 2026, was Remedy's first self-published major single-player game. The game received good reviews (Metacritic 83), and players have received it even better than critics. The game sold over a million copies in about three weeks, making it the fastest-selling game in Remedy's history. Regarding future game releases, the company has Max Payne 1&2 Remake in full production under the subcontracting model, which we expect to be released in early 2027. In addition, the company has an as-yet-unnamed game project in the production readiness stage, which we expect to be Alan Wake 3.

More major game releases ahead in coming years

Remedy guides for 2026 revenue and EBITDA to increase year-on-year. Based on our estimates (2026e revenue 99.7 MEUR, EBITDA 15.9 MEUR), the guidance is clearly beaten following the release of Control Resonant. However, as depreciation increases, EBIT will still remain slightly unprofitable. For 2027, we expect revenue to grow to 113 MEUR and EBITDA to rise to 23.2 MEUR. Growth is supported by the long tail of sales for Control Resonant. In addition, Remedy's share of the game's proceeds will increase once Annapurna's share of the production budget has been recouped. According to our estimates, royalties from Max Payne 1&2 Remake will begin in the second half of 2027. Of the company's 2027 targets, doubling revenue from the 2024 level is met in our estimates, but the EBITDA margin (2027e: 20.6%) falls short of the 30% target. In 2028, we expect EBITDA to rise to 32.3 MEUR (26.2% of revenue). This is driven by Max Payne royalties and the next self-published game, which we expect to be released at the end of the year. Exact visibility into game sales and royalties is weak, and the timing of game releases will continue to cause volatility in Remedy's figures for years to come.

The successful launch of Control Resonant reduced risks, even though the hit game option did not materialize

The successful launch of Control Resonant has, in our view, reduced Remedy's risks, as the scenario of a failed launch is now off the table. We estimate that the game's cash flows, together with a strong balance sheet, will enable the financing and self-publishing of subsequent projects. On the other hand, the hit game option did not materialize, and the short-term element of surprise has been partly priced out of the share. However, based on our estimates for the coming years, the share valuation (2027e-2028e EV/EBITDA of 8x-6x) looks very low following the share price decline. The long-term potential is indicated in part by the base-case value of our DCF model (EUR 22.8). Over the next 12 months, we estimate that the share will be supported by the continuation of Resonant's sales and the likely launch of Max Payne Remake. In addition, further information on Remedy's subsequent game projects may be provided.

Read the full report

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Read more on company page

Key Estimate Figures18.11

202526e27e
Revenue59.599.7112.7
growth-%17.5 %67.6 %13.0 %
EBIT (adj.)-14.9-0.68.5
EBIT-% (adj.)-25.0 %-0.6 %7.5 %
EPS (adj.)-0.96-0.110.48
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.33.2
EV/EBITDA17.213.08.7

Forum discussions

Personally, I expect it to take 1–2 trophies despite this. GOTY is most likely a done deal—GTA6 will take it—but in other categories, I could...
2 hours ago
by Jarnis
5
Hyvää huomenta Remedy-ketjuun! Nyt olisi tarjolla tuoretta laajaa raporttia uudessa digimuodossa. Oli itselle nyt ensimmäinen testi tuon meid...
8 hours ago
by Atte Riikola
43
By the way, I came across this article, which revealed new information that Resonant stayed pretty well within its €50M production budget—or...
yesterday
17
Yep. Even though people joked about it back in the day, the entire industry was ultimately completely right to avoid this November release window...
yesterday
12
That review average for GTA 6 is just insane, so if Resonant snags several runner-up spots, you really just have to be happy with that. Other...
yesterday
by Arvuuttaja
1
Exactly. Control Resonant isn’t nominated in any category where GTA6 isn’t. If GTA6 sweeps all the trophies, Remedy will be left with nothing...
yesterday
by Vinski74
1
Because GTA is taking up absolutely all the media space right now, and the same will continue at the Awards when it wins GOTY.
yesterday
by supremegod
4